ZAZA ANTONIO
- U03, Piano: 3, Stanza: 3011
Pubblicazioni
Maniezzi, C., Eskandr, M., Florindi, C., Ferrandi, M., Barassi, P., Sacco, E., et al. (2024). Early consequences of the phospholamban mutation PLN-R14del+/− in a transgenic mouse model. ACTA PHYSIOLOGICA, 240(3 (March 2024)) [10.1111/apha.14082]. Dettaglio
Nardon, M., Ferri, U., Caffi, G., Bartesaghi, M., Perin, C., Zaza, A., et al. (2024). Kinematics but not kinetics alterations to single-leg drop jump movements following a subject-tailored fatiguing protocol suggest an increased risk of ACL injury. FRONTIERS IN SPORTS AND ACTIVE LIVING, 6 [10.3389/fspor.2024.1418598]. Dettaglio
Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Selective SERCA2a activator as a candidate for chronic heart failure therapy. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1) [10.1186/s12967-024-04874-9]. Dettaglio
Lodola, F., Maniezzi, C., Eskandr, M., Florindi, C., de Boer, R., Silljé, H., et al. (2023). Exploring the pathophysiological role of the PLN-R14del mutation in a novel heterozygous mouse model of dilated cardiomyopathy. Intervento presentato a: Biophysical Society, San Diego, Ca, Usa [10.1016/j.bpj.2022.11.2096]. Dettaglio
Arici, M., Ferrandi, M., Barassi, P., Hsu, S., Torre, E., Luraghi, A., et al. (2023). Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 384(1), 231-244 [10.1124/jpet.122.001335]. Dettaglio